SCHEMBL31401337

SCHEMBL31401337

CC1(C)OB(c2ccc(F)c(-c3cccnc3)c2)OC1(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 5/20 0.45
LPL P06858 4/20 0.45
TDO2 P48775 1/20 0.40
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
ERN1 O75460 1/20 0.39
ROCK1 Q13464 1/20 0.39
PDGFRB P09619 2/20 0.39
KDR P35968 2/20 0.39
GABRA1 P14867 2/20 0.39
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
GABRA5 P31644 2/20 0.39
GABRA3 P34903 2/20 0.39
GABRA2 P47869 1/20 0.39
CYP11B2 P19099 2/20 0.39
NPY5R Q15761 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA5 P30532 1/20 0.39
CHRNA4 P43681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2649267 1.00 LIPG (0.45) LIPGLPLTDO2AKR1C3AKR1C2
SCHEMBL2648752 0.85 LPL (0.47) LIPGLPLTDO2ROCK1PDGFRB
SCHEMBL28470742 0.84 LIPG (0.60) LIPGLPLTDO2ROCK1PDGFRB
SCHEMBL6218782 0.84 LPL (0.48) LIPGLPLTDO2ROCK1PDGFRB
SCHEMBL20615766 0.83 LPL (0.43) LIPGLPLTDO2ROCK1PDGFRB
SCHEMBL2651616 0.82 LPL (0.42) LIPGLPLTDO2ROCK1PDGFRB
SCHEMBL22636737 0.81 LIPG (0.45) LIPGLPLTDO2PDGFRBKDR
SCHEMBL29430844 0.81 LIPG (0.45) LIPGLPLTDO2PDGFRBKDR
SCHEMBL20905062 0.81 LIPG (0.50) LIPGLPLTDO2ROCK1PDGFRB
SCHEMBL31642814 0.80 LIPG (0.48) LIPGLPLPDGFRBKDRCYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed